Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 23:10.7326/ANNALS-25-02404.
doi: 10.7326/ANNALS-25-02404. Online ahead of print.

Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023

Danielle A Rankin  1 , Anna Stahl  1 , Sarah Sabour  1 , Mohammed A Khan  1 , Tiana Armstrong  1 , Jennifer Y Huang  1 , James Baggs  1 , Maroya Spalding Walters  1
Affiliations

Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023

Danielle A Rankin et al. Ann Intern Med. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosure forms are available with the article online.

Figures

Figure.
Figure.
Unadjusted CP-CRE incidence rates per 100 000 persons across an open cohort of U.S. states with required CRE isolate submission, by carbapenemase gene (top) and by organism grouping and carbapenemase gene (bottom), 2019–2023. CP-CRE = carbapenemase-producing carbapenem-resistant Enterobacterales; IMP = active-on-imipenem metallo-β-lactamase; KPC = Klebsiella pneumoniae carbapenemase; NDM = New Delhi metallo-β-lactamase; OXA-48 = oxacillinase; VIM = Verona integron-encoded metallo-β-lactamase.
See this image and copyright information in PMC

References

    1. Martin A, Fahrbach K, Zhao Q, et al. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis. 2018;5:ofy150. doi: 10.1093/ofid/ofy150 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. Emerging Infections Program, Healthcare-Associated Infections – Community Interface Surveillance Report, Multi-site Gram-negative Surveillance Initiative (MuGSI), Carbapenem-Resistant Enterobacterales Surveillance, 2021. Accessed at www.cdc.gov/hai/eip/pdf/mugsi/2021-CRE-Report-508.pdf on 13 March 2025.
    1. Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024:ciae403. doi: 10.1093/cid/ciae403 - DOI - PubMed
    1. Sabour S, Huang JY, Bhatnagar A, et al. Detection and characterization of targeted carbapenem-resistant health care-associated threats: findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019. Antimicrob Agents Chemother. 2021;65:e0110521. doi: 10.1128/AAC.01105-21 - DOI - PMC - PubMed
    1. Rankin DA, Stahl A, Sabour S, et al. Supplemental Materials: Carbapenemase-Producing Enterobacterales Surveillance Study (2019–2023). Accessed at https://github.com/CDCgov/Changes-of-CP-CRE-2019-2023-Supplemental-Files... on 9 September 2025.

LinkOut - more resources